Gigacloud Technology Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Gigacloud Technology Inc trades at $51 (market cap $1.84B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 73× Gigacloud Technology Inc's market cap. Which is the better fit depends on your goals.
| GCT | VRTX | |
|---|---|---|
Market Cap | $1.84B | $134.25B |
Sector | Technology | Health |
52-Week High | $53.25 | $529.65 |
52-Week Low | $25.44 | $376.62 |
Enterprise Value | $1.97B | $128.37B |
Signals from Pluang's Aura AI — not financial advice
GCT trades at $53.25, up 1.62% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.16 versus $0.90 expected, and maintains a 10.65% net income margin. Revenue growth is projected from $1.29B in 2025 to $1.5B in 2026, supported by positive cash flow generation of $120.10M in 2025.
The outlook remains positive given strong profitability metrics (32.34% ROE) and analyst consensus favoring Buy ratings (66.67%). Key risks include potential margin pressure from higher costs and competitive threats in the B2B logistics space. The stock's current valuation at 12.3x P/E appears reasonable relative to growth prospects, though technical indicators show overbought conditions with RSI above 85.
No Aura AI signal available yet.
Trailing returns across standard periods
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →